MARUBBI, DANIELA
 Distribuzione geografica
Continente #
EU - Europa 2.593
AS - Asia 162
NA - Nord America 33
SA - Sud America 22
AF - Africa 4
Totale 2.814
Nazione #
IT - Italia 2.587
SG - Singapore 65
CN - Cina 48
VN - Vietnam 36
US - Stati Uniti d'America 27
AR - Argentina 10
BR - Brasile 8
HK - Hong Kong 6
MX - Messico 4
ID - Indonesia 3
SE - Svezia 2
VE - Venezuela 2
ZA - Sudafrica 2
BD - Bangladesh 1
BG - Bulgaria 1
CA - Canada 1
CO - Colombia 1
EG - Egitto 1
HT - Haiti 1
IQ - Iraq 1
KZ - Kazakistan 1
NL - Olanda 1
PE - Perù 1
PK - Pakistan 1
RU - Federazione Russa 1
TG - Togo 1
UA - Ucraina 1
Totale 2.814
Città #
Genova 1.323
Genoa 853
Vado Ligure 227
Rapallo 175
Singapore 20
Beijing 17
Ho Chi Minh City 17
Ashburn 11
Hanoi 7
Hong Kong 6
Bordighera 4
Haiphong 4
Mexico City 4
Los Angeles 3
Da Nang 2
Stockholm 2
São Paulo 2
Turin 2
Almaty 1
Aquidabã 1
Atlanta 1
Augusta 1
Bella Vista 1
Bismarck 1
Buenos Aires 1
Bắc Ninh 1
Cabimas 1
Cairo 1
Cao Lanh 1
Cartagena 1
Catanduva 1
Caxias do Sul 1
Centurion 1
Chicago 1
Coronel Vidal 1
Curitiba 1
Denver 1
Erbil 1
Formosa 1
Fort Liberté 1
General Rodríguez 1
Glew 1
González Catán 1
Ipojuca 1
Jakarta 1
Johannesburg 1
Karachi 1
Krasnodar 1
Lima 1
Miami 1
Milan 1
New York 1
Phủ Lý 1
Pomigliano d'Arco 1
Presidencia Roque Sáenz Peña 1
Quận Chín 1
Rio de Janeiro 1
Santa Clara 1
Santiago del Estero 1
Seattle 1
Sofia 1
Subang 1
Surabaya 1
Thuận An 1
Tinaco 1
Vancouver 1
Villa Mercedes 1
Vyshneve 1
Wuxi 1
Totale 2.730
Nome #
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma 219
Noninvasive Monitoring of Glioma Growth in the Mouse 174
Cdh4 Down-Regulation Impairs in Vivo Infiltration and Malignancy in Patients Derived Glioblastoma Cells 171
Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration 166
Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. 159
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures 159
Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model 159
Progression from low-to high-grade in a glioblastoma model reveals the pivotal role of immunoediting 156
Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019 156
Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019. 141
Sox2 silencing in glioblastoma tumor initiating cells causes stop of proliferation and loss of tumorigenicity 139
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells 130
Glioblastoma models driven by different mutations converge to the proneural subtype 121
Faithful animal modelling of human glioma by using primary initiating cells and its implications for radiosensitization therapy [ARRIVE 1] 121
Modeling immunoediting in glioma progression 112
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A 103
Natural Killer cells recognize and kill human glioblastoma cells with stem cell-like properties 102
Early clonal extinction in glioblastoma progression revealed by genetic barcoding 99
modeling immunoediting in glioma progression 97
Common features between EGFRVIII and Pdgf-b induced gliomas models. 97
Immunoescape during glioma progression 93
Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription 11
Totale 2.885
Categoria #
all - tutte 9.683
article - articoli 8.189
book - libri 0
conference - conferenze 1.494
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.366


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 14 6 17 13 40 16 14
2021/2022264 16 21 9 27 3 25 13 59 20 24 13 34
2022/2023205 18 21 6 25 23 26 3 18 26 0 37 2
2023/2024244 4 22 10 31 25 48 13 10 12 10 14 45
2024/2025577 28 38 23 55 64 51 41 146 19 24 43 45
2025/2026471 125 18 51 92 149 36 0 0 0 0 0 0
Totale 2.885